S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
pixel
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
pixel
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
pixel
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
pixel
Log in
NASDAQ:ACRS

Aclaris Therapeutics News Headlines

$21.31
+0.17 (+0.80 %)
(As of 03/5/2021 12:00 AM ET)
Add
Compare
Today's Range
$19.85
Now: $21.31
$21.90
50-Day Range
$5.88
MA: $19.69
$24.21
52-Week Range
$0.70
Now: $21.31
$25.48
Volume605,874 shs
Average Volume3.98 million shs
Market Capitalization$1.10 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.2

Headlines

Aclaris Therapeutics (NASDAQ ACRS) News Headlines Today

Source:
SourceHeadline
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) to Post Q1 2021 Earnings of ($0.27) Per Share, SVB Leerink ForecastsAclaris Therapeutics, Inc. (NASDAQ:ACRS) to Post Q1 2021 Earnings of ($0.27) Per Share, SVB Leerink Forecasts
americanbankingnews.com - March 5 at 8:36 AM
Short Interest in Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Grows By 52.7%Short Interest in Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Grows By 52.7%
americanbankingnews.com - March 5 at 4:14 AM
Aclaris Therapeutics (NASDAQ:ACRS) Shares Up 8%Aclaris Therapeutics (NASDAQ:ACRS) Shares Up 8%
americanbankingnews.com - March 1 at 7:38 PM
William Blair Weighs in on Aclaris Therapeutics, Inc.s Q1 2022 Earnings (NASDAQ:ACRS)William Blair Weighs in on Aclaris Therapeutics, Inc.'s Q1 2022 Earnings (NASDAQ:ACRS)
americanbankingnews.com - March 1 at 3:37 AM
Aclaris Therapeutics (NASDAQ:ACRS) Posts  Earnings Results, Beats Expectations By $0.01 EPSAclaris Therapeutics (NASDAQ:ACRS) Posts Earnings Results, Beats Expectations By $0.01 EPS
americanbankingnews.com - February 26 at 1:46 PM
Aclaris Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides a Corporate UpdateAclaris Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides a Corporate Update
finance.yahoo.com - February 25 at 8:29 AM
Aclaris Therapeutics (NASDAQ:ACRS) Stock Price Up 8.6%Aclaris Therapeutics (NASDAQ:ACRS) Stock Price Up 8.6%
americanbankingnews.com - February 22 at 7:20 PM
Aclaris Therapeutics to Participate in Upcoming Investor ConferencesAclaris Therapeutics to Participate in Upcoming Investor Conferences
finance.yahoo.com - February 22 at 9:00 AM
Aclaris Therapeutics (NASDAQ:ACRS) Stock Price Down 5.4%Aclaris Therapeutics (NASDAQ:ACRS) Stock Price Down 5.4%
americanbankingnews.com - February 18 at 7:28 PM
Aclaris Therapeutics (NASDAQ:ACRS) Reaches New 12-Month High at $25.32Aclaris Therapeutics (NASDAQ:ACRS) Reaches New 12-Month High at $25.32
americanbankingnews.com - February 12 at 2:58 PM
Aclaris Therapeutics (NASDAQ:ACRS) Trading Up 6.7%Aclaris Therapeutics (NASDAQ:ACRS) Trading Up 6.7%
americanbankingnews.com - February 10 at 7:34 PM
Aclaris Therapeutics to Participate in the 10th Annual SVB Leerink Global Healthcare ConferenceAclaris Therapeutics to Participate in the 10th Annual SVB Leerink Global Healthcare Conference
finance.yahoo.com - February 10 at 9:06 AM
Gaining Ground After A Tough Couple Of WeeksGaining Ground After A Tough Couple Of Weeks
finance.yahoo.com - January 25 at 7:34 PM
Aclaris aims to raise $96 million through stock offering after shares soarAclaris aims to raise $96 million through stock offering after shares soar
bizjournals.com - January 20 at 9:29 PM
Aclaris Therapeutics stock jumps on positive data for drug developed by St. Louis-based unitAclaris Therapeutics' stock jumps on positive data for drug developed by St. Louis-based unit
bizjournals.com - January 20 at 4:22 PM
How High Is the Blue Sky for Aclaris Stock? Analyst Weighs InHow High Is the Blue Sky for Aclaris Stock? Analyst Weighs In
finance.yahoo.com - January 20 at 4:21 PM
Aclaris Announces Pricing of Public Offering of Common StockAclaris Announces Pricing of Public Offering of Common Stock
finance.yahoo.com - January 20 at 11:21 AM
Aclaris (ACRS) Up on Preliminary Data for MK2 Inhibitor in RAAclaris (ACRS) Up on Preliminary Data for MK2 Inhibitor in RA
finance.yahoo.com - January 20 at 11:21 AM
Aclaris Explodes 220% On ‘Positive Data’ From Rheumatoid Arthritis TrialAclaris Explodes 220% On ‘Positive Data’ From Rheumatoid Arthritis Trial
finance.yahoo.com - January 20 at 6:20 AM
Is Aclaris Therapeutics a Stock to Buy After Nearly 200% Run-Up and Now This?Is Aclaris Therapeutics a Stock to Buy After Nearly 200% Run-Up and Now This?
msn.com - January 19 at 8:20 PM
Aclaris Therapeutics stock skyrockets 220% on positive data for potential arthritis treatmentAclaris Therapeutics' stock skyrockets 220% on positive data for potential arthritis treatment
bizjournals.com - January 19 at 8:20 PM
Aclaris Announces Proposed Public Offering of Common StockAclaris Announces Proposed Public Offering of Common Stock
finance.yahoo.com - January 19 at 8:20 PM
Aclaris Triples After Progress in Rheumatoid Arthritis Drug TrialAclaris Triples After Progress in Rheumatoid Arthritis Drug Trial
finance.yahoo.com - January 19 at 8:20 PM
Stock Alert: Aclaris Therapeutics Surges 160%Stock Alert: Aclaris Therapeutics Surges 160%
nasdaq.com - January 19 at 3:19 PM
Aclaris Therapeutics stock more than triples after positive data on arthritis treatment trialAclaris Therapeutics stock more than triples after 'positive' data on arthritis treatment trial
finance.yahoo.com - January 19 at 3:19 PM
Aclaris Therapeutics Announces Positive Preliminary Topline Data from 12-Week Phase 2a Trial of Oral ATI-450 for Moderate to Severe Rheumatoid ArthritisAclaris Therapeutics Announces Positive Preliminary Topline Data from 12-Week Phase 2a Trial of Oral ATI-450 for Moderate to Severe Rheumatoid Arthritis
finance.yahoo.com - January 19 at 8:35 AM
Is Aclaris Therapeutics (NASDAQ:ACRS) Weighed On By Its Debt Load?Is Aclaris Therapeutics (NASDAQ:ACRS) Weighed On By Its Debt Load?
finance.yahoo.com - December 29 at 7:19 AM
Implied Volatility Surging for Aclaris Therapeutics (ACRS) Stock OptionsImplied Volatility Surging for Aclaris Therapeutics (ACRS) Stock Options
finance.yahoo.com - December 23 at 1:56 PM
Is ACRS A Good Stock To Buy Now?Is ACRS A Good Stock To Buy Now?
finance.yahoo.com - December 16 at 1:16 AM
Aclaris Therapeutics Announces Formation of New Scientific Advisory BoardAclaris Therapeutics Announces Formation of New Scientific Advisory Board
finance.yahoo.com - December 15 at 10:09 AM
Aclaris Therapeutics to Participate in the Evercore ISI 3rd Annual HealthCONx ConferenceAclaris Therapeutics to Participate in the Evercore ISI 3rd Annual HealthCONx Conference
finance.yahoo.com - November 16 at 8:51 PM
How Much Does Aclaris Therapeutics (NASDAQ:ACRS) CEO Make?How Much Does Aclaris Therapeutics' (NASDAQ:ACRS) CEO Make?
finance.yahoo.com - November 14 at 8:44 AM
Aclaris Therapeutics (ACRS) Reports Q3 Loss, Tops Revenue EstimatesAclaris Therapeutics (ACRS) Reports Q3 Loss, Tops Revenue Estimates
finance.yahoo.com - November 4 at 1:44 PM
Aclaris Therapeutics EPS beats by $0.05, misses on revenueAclaris Therapeutics EPS beats by $0.05, misses on revenue
seekingalpha.com - November 4 at 8:43 AM
Aclaris Therapeutics Reports Third Quarter 2020 Financial Results and Provides a Corporate UpdateAclaris Therapeutics Reports Third Quarter 2020 Financial Results and Provides a Corporate Update
finance.yahoo.com - November 4 at 8:43 AM
Dosing underway for Aclariss ATI-1777 in mid-stage atopic dermatitis studyDosing underway for Aclaris's ATI-1777 in mid-stage atopic dermatitis study
seekingalpha.com - October 20 at 8:38 AM
Aclaris Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial of ATI-1777, an Investigational Topical “Soft” JAK 1/3 Inhibitor, for the Treatment of Moderate to Severe Atopic DermatitisAclaris Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial of ATI-1777, an Investigational Topical “Soft” JAK 1/3 Inhibitor, for the Treatment of Moderate to Severe Atopic Dermatitis
finance.yahoo.com - October 20 at 8:38 AM
Aclaris (ACRS) Upgraded to Buy: Here's What You Should KnowAclaris (ACRS) Upgraded to Buy: Here's What You Should Know
finance.yahoo.com - August 13 at 1:35 PM
Aclaris Therapeutics EPS beats by $0.07, beats on revenueAclaris Therapeutics EPS beats by $0.07, beats on revenue
seekingalpha.com - August 7 at 11:33 AM
Aclaris Therapeutics Reports Second Quarter 2020 Financial Results and Provides R&D and Business HighlightsAclaris Therapeutics Reports Second Quarter 2020 Financial Results and Provides R&D and Business Highlights
finance.yahoo.com - August 7 at 11:33 AM
Aclaris Therapeutics (ACRS) Reports Q2 Loss, Tops Revenue EstimatesAclaris Therapeutics (ACRS) Reports Q2 Loss, Tops Revenue Estimates
finance.yahoo.com - August 7 at 11:33 AM
Will Aclaris Therapeutics (ACRS) Report Negative Q2 Earnings? What You Should KnowWill Aclaris Therapeutics (ACRS) Report Negative Q2 Earnings? What You Should Know
finance.yahoo.com - August 6 at 2:10 PM
Aclaris Therapeutics IncAclaris Therapeutics Inc
www.bloomberg.com - July 30 at 11:55 PM
Stock Alert: Aclaris Therapeutics Up 40%Stock Alert: Aclaris Therapeutics Up 40%
www.nasdaq.com - July 20 at 1:11 PM
Aclaris gains ~8% after filing IND for ATI-1777 in dermatitisAclaris gains ~8% after filing IND for ATI-1777 in dermatitis
seekingalpha.com - July 7 at 10:27 PM
Aclaris Therapeutics Submits Investigational New Drug Application for ATI-1777, a Topical “Soft” JAK1/3 Inhibitor, for the Treatment of Moderate to Severe Atopic DermatitisAclaris Therapeutics Submits Investigational New Drug Application for ATI-1777, a Topical “Soft” JAK1/3 Inhibitor, for the Treatment of Moderate to Severe Atopic Dermatitis
finance.yahoo.com - July 7 at 5:26 PM
Two more suburban Philadelphia biopharm firms join battle against Covid-19Two more suburban Philadelphia biopharm firms join battle against Covid-19
www.bizjournals.com - June 19 at 1:29 PM
P/E Ratio Insights for Aclaris TherapeuticsP/E Ratio Insights for Aclaris Therapeutics
www.benzinga.com - June 17 at 1:28 PM
Aclaris Therapeutics Takes the Next Big Step Toward COVID TreatmentAclaris Therapeutics Takes the Next Big Step Toward COVID Treatment
247wallst.com - June 17 at 1:28 PM
Aclaris Rips Higher Following FDA Approval Of Coronavirus StudyAclaris Rips Higher Following FDA Approval Of Coronavirus Study
www.benzinga.com - June 17 at 1:28 PM
This page was last updated on 3/6/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.